These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 3568016)
21. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse. Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194 [TBL] [Abstract][Full Text] [Related]
22. [A comparative evaluation of tumor markers (TPA and CEA) in various malignant neoplasms at an advanced stage]. Meregalli M; Antoniazzi V; Torchio G; Colombo E; Bocchi M; Sonzini E; Lino S Minerva Med; 1989 Apr; 80(4):345-7. PubMed ID: 2725935 [TBL] [Abstract][Full Text] [Related]
23. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer]. Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515 [TBL] [Abstract][Full Text] [Related]
24. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer]. Engel K; Schmid H; Hanke J; Kaufmann M; Müller A Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077 [TBL] [Abstract][Full Text] [Related]
25. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144 [TBL] [Abstract][Full Text] [Related]
26. [Ferritin, CEA and TPA as tumor markers in breast neoplasms]. Bonanni F; Folco U; Giudici Cipriani A; Buffa E; Amedeo A; Bertolotto M; Rembado R; Barbetti V; Guglieri F Minerva Med; 1985 Sep; 76(34-35):1533-4. PubMed ID: 4034052 [TBL] [Abstract][Full Text] [Related]
27. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]. Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513 [TBL] [Abstract][Full Text] [Related]
28. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449 [TBL] [Abstract][Full Text] [Related]
29. Optimizing tumor markers in breast cancer: monitoring, prognosis, and therapy control. Staab HJ; Ahlemann LM; Anderer FA; Zwirner M; Schindler AE Cancer Detect Prev; 1985; 8(1-2):35-45. PubMed ID: 4064050 [TBL] [Abstract][Full Text] [Related]
30. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Lai IR; Lee WJ; Huang MT; Lin HH Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226 [TBL] [Abstract][Full Text] [Related]
31. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA. Willsher PC; Beaver J; Blamey RW; Robertson JF Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057 [TBL] [Abstract][Full Text] [Related]
32. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer]. Zheng H; Luo RC Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113 [TBL] [Abstract][Full Text] [Related]
33. [Clinical usefulness of tumor markers in breast cancer]. Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956 [TBL] [Abstract][Full Text] [Related]
34. Clinical utility of the combined use of plurime tumor markers in human breast cancer. Neri B; Bartalucci S; Cataliotti L; Distante V; Tommasi M; Ciapini A Cancer Detect Prev; 1988; 13(2):115-21. PubMed ID: 3072081 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258 [TBL] [Abstract][Full Text] [Related]
36. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. von Kleist S; Hesse Y; Kananeeh H Anticancer Res; 1996; 16(4B):2325-31. PubMed ID: 8694564 [TBL] [Abstract][Full Text] [Related]
37. How can treatment response be measured in breast cancer patients? van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398 [TBL] [Abstract][Full Text] [Related]
38. Significance of serum phosphohexose isomerase in gastrointestinal cancer at different stages. Baumann M; Brand K; Giedl J; Hermanek P; Ruf S; Scheele J; Hoferichter S; Gall FP Oncology; 1988; 45(3):153-8. PubMed ID: 3368192 [TBL] [Abstract][Full Text] [Related]
39. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473 [TBL] [Abstract][Full Text] [Related]
40. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]